High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial
Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Fátima Cardoso(Breast Cancer Alliance), Luca Russo(University of Milan), Lisette Stork‐Sloots(Agendia (Netherlands)), Annuska M. Glas(Leiden University Medical Center), Leen Slaets(European Organisation for Research and Treatment of Cancer), Patrizia Dell’Orto(University of Milan), Jeroen van den Akker(Agendia (Netherlands)), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Martine Piccart(Université Libre de Bruxelles), Femke A. de Snoo(Agendia (Netherlands)), Laura van’t Veer(University of California, San Francisco), Emiel J. Rutgers(Oncode Institute)
Cited by 65
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k